Literature DB >> 21220598

Leukemia stem cells and microenvironment: biology and therapeutic targeting.

Marina Y Konopleva1, Craig T Jordan.   

Abstract

Acute myelogenous leukemia is propagated by a subpopulation of leukemia stem cells (LSCs). In this article, we review both the intrinsic and extrinsic components that are known to influence the survival of human LSCs. The intrinsic factors encompass regulators of cell cycle and prosurvival pathways (such as nuclear factor kappa B [NF-κB], AKT), pathways regulating oxidative stress, and specific molecular components promoting self-renewal. The extrinsic components are generated by the bone marrow microenvironment and include chemokine receptors (CXCR4), adhesion molecules (VLA-4 and CD44), and hypoxia-related proteins. New strategies that exploit potentially unique properties of the LSCs and their microenvironment are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220598      PMCID: PMC4874213          DOI: 10.1200/JCO.2010.31.0904

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  99 in total

Review 1.  Leukaemia stem cells and the evolution of cancer-stem-cell research.

Authors:  Brian J P Huntly; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

2.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

3.  Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

Authors:  Meike Burger; Tanja Hartmann; Myriam Krome; Justyna Rawluk; Hirokazu Tamamura; Nobutaka Fujii; Thomas J Kipps; Jan A Burger
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

Review 4.  Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.

Authors:  T L Holyoake; X Jiang; M W Drummond; A C Eaves; C J Eaves
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

5.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

6.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

7.  Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats.

Authors:  B T Mortensen; P O Jensen; N Helledie; P O Iversen; E Ralfkiaer; J K Larsen; M T Madsen
Journal:  Br J Haematol       Date:  1998-07       Impact factor: 6.998

8.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

Authors:  David C Taussig; Farideh Miraki-Moud; Fernando Anjos-Afonso; Daniel J Pearce; Kirsty Allen; Christopher Ridler; Debra Lillington; Heather Oakervee; Jamie Cavenagh; Samir G Agrawal; T Andrew Lister; John G Gribben; Dominique Bonnet
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

9.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

10.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

View more
  181 in total

1.  The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Authors:  Benjamin Mizukawa; Eric O'Brien; Daniel C Moreira; Mark Wunderlich; Cindy L Hochstetler; Xin Duan; Wei Liu; Emily Orr; H Leighton Grimes; James C Mulloy; Yi Zheng
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

2.  PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.

Authors:  Linhua Jin; Yoko Tabe; Kensuke Kojima; Masato Shikami; Julina Benito; Vivian Ruvolo; Rui-Yu Wang; Teresa McQueen; Stefan O Ciurea; Takashi Miida; Michael Andreeff; Marina Konopleva
Journal:  J Mol Med (Berl)       Date:  2013-08-18       Impact factor: 4.599

3.  Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.

Authors:  Yun Dai; Shuang Chen; Li Wang; Xin-Yan Pei; Vanessa L Funk; Lora B Kramer; Paul Dent; Steven Grant
Journal:  J Biol Chem       Date:  2011-08-04       Impact factor: 5.157

Review 4.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

Review 5.  Advances in understanding the leukaemia microenvironment.

Authors:  Yoko Tabe; Marina Konopleva
Journal:  Br J Haematol       Date:  2014-01-09       Impact factor: 6.998

6.  Treatment of acute myeloid leukemia in the elderly.

Authors:  Elihu H Estey
Journal:  Haematologica       Date:  2011-06       Impact factor: 9.941

7.  Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.

Authors:  Linhua Jin; Yoko Tabe; Hongbo Lu; Gautam Borthakur; Takashi Miida; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Lett       Date:  2012-10-02       Impact factor: 8.679

8.  CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.

Authors:  Masayuki Iwasaki; Michaela Liedtke; Andrew J Gentles; Michael L Cleary
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

9.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Authors:  Bing Z Carter; Po Yee Mak; Duncan H Mak; Yuexi Shi; Yihua Qiu; James M Bogenberger; Hong Mu; Raoul Tibes; Hui Yao; Kevin R Coombes; Rodrigo O Jacamo; Teresa McQueen; Steven M Kornblau; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

10.  Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.

Authors:  S Zhang; I Mercado-Uribe; Z Xing; B Sun; J Kuang; J Liu
Journal:  Oncogene       Date:  2013-03-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.